

Supplementary material for ‘Siponimod: disentangling disability and relapses in secondary progressive multiple sclerosis’

Authors: Bruce A C Cree, Baldur Magnusson, Nicolas Rouyrre, Robert J Fox, Gavin Giovannoni, Patrick Vermersch, Amit Bar-Or, Ralf Gold, Daniela Piani Meier, Göril Karlsson, Davorka Tomic, Christian Wolf, Frank Dahlke and Ludwig Kappos

Supplementary Table 1

Risk of 3mCDP and of 6mCDP with siponimod relative to placebo in patients with no clinical relapses, those with no clinical relapses and no new or enlarging T2 lesions and those with no clinical relapses and fewer than two T2 lesions

Endpoint/timepoint	<u>No relapses</u>		<u>No relapses and no new/enlarging T2 lesions</u>		<u>No relapses and < 2 new/enlarging T2 lesions</u>	
	Probability of	Risk Ratio	Probability of	Risk Ratio	Probability of	Risk Ratio
	belonging to stratum	(95% CrI)	belonging to stratum	(95% CrI)	belonging to stratum	(95% CrI)
3mCDP						
12 months	0.87	0.80 (0.56, 1.08)	0.41	0.71 (0.23, 1.33)	0.52	0.71 (0.22, 1.27)
24 months	0.80	0.82 (0.48, 1.32)	0.34	0.79 (0.22, 1.93)	0.47	0.75 (0.21, 1.67)
6mCDP						
12 months	0.87	0.67 (0.44, 0.93)	0.41	0.59 (0.19, 1.09)	0.52	0.61 (0.20, 1.11)
24 months	0.80	0.71 (0.37, 1.21)	0.34	0.71 (0.19, 1.82)	0.47	0.74 (0.22, 1.74)

3mCDP: 3 month confirmed disability progression; 6mCDP: 6 month confirmed disability progression; CrI: credible intervals